The discovery of a drug that, according to the first trials, slows the progression of a type of breast cancer – HER2 positive with metastasis – in more than 75% of patients, and is even capable of eliminating the tumor in the 16% is great news for those affected by this disease. A great success for the International Breast Cancer Center (IBCC), led by the oncologist Javier Cortés Castán, who has called on the European Medicines Agency (EMA) to allow its use in certain cases.
–
